![Slate Business artwork](https://is4-ssl.mzstatic.com/image/thumb/Podcasts113/v4/62/7b/4f/627b4fcc-7eba-686d-3e01-4a0e7a00d752/mza_10827166523127370665.jpg/100x100bb.jpg)
What Next TBD: The Summer Vaccine of the Future
Slate Business
English - September 04, 2022 07:00 - 20 minutesManagement Business News Business News Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Slate Money: Quiet Quitting
Next Episode: What Next TBD: Can A.I. Make Great Art?
LYMErix, the first vaccine against Lyme, was pulled from the market amid poor sales and pressure from the public. Now, over 20 years later, a new vaccine is in late-stage trials.
Guest: Cassandra Willyard
Host: Lizzie O'Leary
Learn more about your ad choices. Visit megaphone.fm/adchoices
LYMErix, the first vaccine against Lyme, was pulled from the market amid poor sales and pressure from the public. Now, over 20 years later, a new vaccine is in late-stage trials.
Guest: Cassandra Willyard
Host: Lizzie O'Leary
Learn more about your ad choices. Visit megaphone.fm/adchoices